
==== Front
Cancer Immunol Immunother
Cancer Immunol Immunother
Cancer Immunology, Immunotherapy : CII
0340-7004
1432-0851
Springer Berlin Heidelberg Berlin/Heidelberg

39105809
3778
10.1007/s00262-024-03778-3
Research
Conversion of anti-tissue factor antibody sequences to chimeric antigen receptor and bi-specific T-cell engager format
Saunderson S. C. 1
Halpin J. C. 12
Tan G. M. Y. 13
Shrivastava P. 1
McLellan A. D. alex.mclellan@otago.ac.nz

1
1 https://ror.org/01jmxt844 grid.29980.3a 0000 0004 1936 7830 Department of Microbiology and Immunology, University of Otago, Dunedin, 9016 New Zealand
2 https://ror.org/05k0s5494 grid.413973.b 0000 0000 9690 854X Present Address: The Children’s Hospital Westmead, The Children’s Hospital Westmead CRN Hawksbury Road and Hainsworth Street, Westmead, NSW 2145 Australia
3 https://ror.org/04xs57h96 grid.10025.36 0000 0004 1936 8470 Present Address: Molecular and Clinical Cancer Medicine, The University of Liverpool, Crown St., Liverpool, UK
6 8 2024
6 8 2024
10 2024
73 10 1956 6 2024
8 7 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Background

The efficacy of antibody-targeted therapy of solid cancers is limited by the lack of consistent tumour-associated antigen expression. However, tumour-associated antigens shared with non-malignant cells may still be targeted using conditionally activated-antibodies, or by chimeric antigen receptor (CAR) T cells or CAR NK cells activated either by the tumour microenvironment or following 'unlocking' via multiple antigen-recognition. In this study, we have focused on tissue factor (TF; CD142), a type I membrane protein present on a range of solid tumours as a basis for future development of conditionally-activated BiTE or CAR T cells. TF is frequently upregulated on multiple solid tumours providing a selective advantage for growth, immune evasion and metastasis, as well as contributing to the pathology of thrombosis via the extrinsic coagulation pathway.

Methods

Two well-characterised anti-TF monoclonal antibodies (mAb) were cloned into expression or transposon vectors to produce single chain (scFv) BiTE for assessment as CAR and CD28-CD3-based CAR or CD3-based BiTE. The affinities of both scFv formats for TF were determined by surface plasmon resonance. Jurkat cell line-based assays were used to confirm the activity of the BiTE or CAR constructs.

Results

The anti-TF mAb hATR-5 and TF8-5G9 mAb were shown to maintain their nanomolar affinities following conversion into a single chain (scFv) format and could be utilised as CD28-CD3-based CAR or CD3-based BiTE format.

Conclusion

Because of the broad expression of TF on a range of solid cancers, anti-TF antibody formats provide a useful addition for the development of conditionally activated biologics for antibody and cellular-based therapy.

Supplementary Information

The online version contains supplementary material available at 10.1007/s00262-024-03778-3.

Keywords

Chimeric antigen receptor
Bi-specific T cell engager
Tissue factor
Surface plasmon resonance
http://dx.doi.org/10.13039/501100009193 Marsden Fund MFP-UOO1808 Saunderson S. C. http://dx.doi.org/10.13039/501100001505 Health Research Council of New Zealand 21-212 21-212 Halpin J. C. McLellan A. D. University of OtagoOpen Access funding enabled and organized by CAUL and its Member Institutions

issue-copyright-statement© Springer-Verlag GmbH Germany, part of Springer Nature 2024
==== Body
pmcIntroduction

Immunotherapy of solid cancers is confounded by the lack of reliably expressed tumour-associated antigens and heterogeneity within tumour masses [1]. Chimeric antigen receptor (CAR) T cells have been successfully utilised for the treatment of haematopoietic malignancies, however the expansion into the area of solid tumour treatment has not been as successful [1]. Solid tumours present a number of challenges that prevent effective immunotherapy. In addition to their physical and biological factors, such as the immunosuppressive tumour microenvironment that can lead to the exclusion of effector lymphocytes from the tumour mass, solid tumours are usually heterogeneous in their surface antigen expression [1]. Specific targeting to tumour-associated antigens (TAA) is essential to maximise anti-cancer effects while avoiding systemic toxicities [2, 3]. Immunotherapy of solid tumours face a number of challenges including the immunosuppressive tumour environment, and low level TAA expression on some non-malignant tissues leading to on-target off-tumour effects [4, 5].

Antibody sequences form the recognition domain of clinically approved therapies for blood cancers including bi-specific T-cell engagers (BiTEs) and CAR T cells. All FDA-approved CAR possess an N-terminal scFv domain, although other experimental anti-tumour ligands have been proposed [6, 7]. BITEs target T cell activation molecules (e.g. the CD3 complex) together with an antigen expressed on the surface of on tumour cells. The tethering of T cells to cancer cells provokes potent T cell activation and destruction of tumour cells.

CAR T cells are engineered with surface expressed immunoglobulin-derived single chain variable fragments (scFv) linked to intracellular T cell signalling domains such as CD3, CD28, or 41BB, thus enabling T cells to directly target cells expressing a specific TAA expressed on tumour cells [8, 9]. Targeting more than one antigen can expand tumour recognition and mitigate immune escape through loss of the expression of a single antigen. Requiring dual recognition can also improve safety. Alternatively, off-switches can be used to prevent unwanted reaction to non-malignant tissue. For example, split CAR designs require recognition of two TAA for full T cell activation due to the presence of a singular intracellular activation domain on each CAR. While bi-specific T cell engager (BiTE) molecules that link two distinct scFv together, one specific for T cells, e.g. anti-CD3 on CAR T cells or endogenous tumour infiltrating T cells (TILs), and the other towards an antigen of choice, e.g. a TAA [10].

In order to expand the possibilities of targeting solid tumour-associated TAA, we investigated well-characterised anti-tissue factor monoclonal antibodies (mAb) for conversion into CAR or as a bi-specific T cell engager utilising and anti-CD3 gamma/epsilon BiTE arm as a proof of concept using an antigen widely expressed on solid tumours and one that is associated with poor prognosis. Tissue factor (TF; CD142) is highly overexpressed on many solid tumours, such as pancreatic and triple-negative breast cancers, at levels 1000-fold higher than normal tissue [11–13]. This also includes expression within the neo-vasculature of the tumour, overall making TF a potentially useful TAA to target in tumour immunotherapy [11, 13–17]. Dysregulation of gene expression due to loss of tumour suppression results in over-expression of TF in a number of cancers [11, 18, 19]. TF expression in tumour cells is linked to the mutations in p53 and phosphatase and tensin homolog PTEN [19], resulting in dysregulation of TF expression. TF expression enhances cancer progression and metastasis, not only via coagulation and platelet activation but also by TF activation of protease activated receptor-2 (PAR-2) signalling [11, 19–25].

TF binds to circulating coagulation factor VIIa (FVIIa) to form a TF and FVIIa catalytic complex, initiating the extrinsic coagulation pathway and resulting rapid and profound coagulation, often associated with pathological events, such as venous thromboembolism. We have previously shown that exogenous Factor V binds to tumour-associated TF, particularly when the TF is associated with phosphatidylserine-exposed tumour-membranes and vesicles [26, 27]. The TF coagulation factor is absent from haematopoietic cells, but is expressed as part of the haemostatic envelope on cells surrounding the vasculature [18], primarily in subendothelial cells which anatomically sequester TF from the blood [28–30]. While this reduces the interaction between CAR T cells and non-malignant cells expressing TF, in turn decreasing on-target off-tumour effects, there are still reports of low level TF expression within the body. TF targeting therefore carries the potential to cause life-threatening on-target off-tumour affects, further emphasising the use of a dual recognition immunotherapy system [30].

In this study, we have investigated the ability to express two well-known anti-human TF mAb (clones TF8-5G9 and hATR-5) as scFvFc and confirm their binding affinity to TF. Further to this we developed two functional 2nd generation CAR constructs derived from TF8-5G9 and hATR-5 scFv. However, as solid tumour immunotherapies targeting a single antigen run a greater risk of life-threatening on-target off-tumour effects, it may be prudent to employ a second antigen or target to further reduce risks [2]. We therefore generated an anti-TF/-CD3 BiTE from the TF8-5G9 and OKT3 scFv which successfully targeted both the TF tumour cell and CD3 of T cells. This study has further emphasised the immunotherapeutic potential of targeting TF expressed by tumour cells.

Materials and methods

Cell culture

Jurkat (clone E6.1) and MDA-MB-231, or HEK293T were cultured respectively at 37 °C with 5% CO2 in RPMI media supplemented with 5% foetal calf serum (FCS; Pan Biotech), 55 µM β-mercaptoethanol, 100 U/mL penicillin and 100 µg/mL streptomycin (unless otherwise stated), or 10% FCS/DMEM media supplemented with 100 U/mL penicillin and 100 µg/mL streptomycin (unless otherwise stated). Expi293F cells were cultured at 37 °C with 8% CO2 and orbital shaking (130 rpm) in Expi293F expression media (ThermoFisher).

Constructs

Codon optimised anti-human TF scFv sequences were derived from the amino acid sequences of murine mAb clone TF8-5G9 (PDB: 1FGN; [31, 32]) and the murine-humanised mAb clone hATR-5 (PDB: 1UJ3; [33]). Plasmid insert gene constructs and DNA sequences are listed in supplementary data.

Protein expression and purification

Planktonic Expi293F cells (37.5 × 106 in 15 mL) were transfected with 15 µg of pcDNA3.1(-):TF85G9 scFvFc, hATR-5 scFvFc, or human TF-Fc (Genscript), or pSBbiGP:OKT3-TF85G9 BiTE (His-tagged; OKT3 VH-VL and TF85G9 VH-VL joined via glycine-serine linkers; IDT geneblock) using the Gibco Expifectamine293 transfection kit as per the manufacturer’s instructions (Gibco #A14524). Cells were incubated until cell viability decreased to approximately 30%, after which cell supernatant was centrifuged at 450 × g for five minutes, followed by 2000 × g for 20 min, and supernatant 0.2 µm filtered. Fc-fusion proteins were purified by Protein A chromatography (Pierce #20,356), eluted in 500 µL fractions of 100 mM glycine (pH 3.0) and neutralised with 100 µL of 1 M Tris–HCl (pH 9.0). His-tagged proteins were purified by Protino Nickel-NTA agarose column (MN745400.25) as per the manufacturer’s instructions, prior to dialysis with phosphate-buffered saline (PBS). For SPR, fusion proteins were further purified by size exclusion chromatography (Superdex 200 10/300 GL column) with PBS-EP (0.01% Tween20, 300 mM NaCl PBS, pH 7.4). In brief, proteins were centrifuged at 15,000 × g to remove precipitate, followed by incubation with 2 mM DTT for 30 min on ice. Proteins were then injected in the column and run at a flow rate of 0.5 mL/min and 500 µL fractions collected. Boiled and reduced proteins were run on a 4–12% BOLT Bis–Tris gel, before stained with Coomassie blue.

SPR

SPR experiments were carried out using a Biacore X100 instrument at 25 °C. Human TF-Fc was immobilised to the surface of a CM5 sensor chip (target of 500 response units) in 10 mM sodium acetate pH 4.0 with a flow rate of 10 µL/min. Serial dilutions (18.75–3.125 nM) of TF8-5G9 scFvFc were made with PBS-EP and run over the sensor chip for two cycles (flow rate 30 µL/min; contact time 180 s; dissociation time 600 s). Sensograms were globally fitted with a 1:1 binding model and binding kinetics determined with BIAevaluation software.

CAR generation

Second-generation CAR constructs (scFv-c-myc tag-CD8 hinge-CD28-CD3ζ) were generated from the variable fragment sequences of anti-human tissue factor mAb TF8-5G9 and hATR-5. A sleeping beauty transposon system was utilised for transfection of the CAR cassette into Jurkat T cells. Plasmids (9 µg of pSBbiGP (or RP where stated) and 1 µg of pCMV(CAT)T7-SB100) were introduced into cells via electroporation with a neon transfection system with 100 µL gold tips (1350 V, 10 ms, three pulses) and cultured with antibiotic free media for at least 48 h, before stably transfected cells selected for with 2 µg/mL puromycin. TF8-5G9 or hATR-5 CAR T cells were incubated with 2 µg/mL anti-c-myc-biotin (Biolegend #908,805) in 0.1% BSA/PBS/2 mM EDTA for 30 min on ice, biotin was then detected with 4 µg/mL streptavidin-allophycocyanin (Biolegend #405,207) and incubated as previously described. Cells were analysed for GFP or RFP (as stated) and c-myc expression with a BD LSR Fortessa, and subject to both FSc and SSc doublet discrimination prior to further analysis with FlowJo v10.7.2.

In vitro CAR assay

A 24-well plate was seeded with TF-expressing cell line MDA-MB-231 (1 × 106 cells/mL; 500 μL/well) in 5% FCS/RPMI for 24 h at 37 °C with 5% CO2. Alternatively, wells were coated with human TF-Fc fusion protein (10–1.25 µg/mL; 300 μL/well) overnight at 4 °C, wells were then rinsed twice with PBS. CAR-T or untransfected Jurkat cells (1 × 106 cells/mL; 600 μL/well) in 5% FCS/RPMI were then added to the plates and incubated at 37 °C with 5% CO2 for 24 h. Positive control 25 ng/mL PMA/0.75 µg/mL ionomycin, or negative controls as stated were also included. Cell culture supernatant was analysed by anti-human IL-2 ELISA.

In vitro BiTE assay

HEK293T cells (2 × 105) were seeded in 24-well plates in 500 μL of antibiotic-free media and incubated at 37 °C with 5% CO2. At 24 h, HEK293T were transiently transfected with a total of 500 ng of plasmid DNA (pcDNA3.1( +): Human full-length TF, pSBbiGP: OKT3-TF85G9 BiTE, pSBbiGP: empty vector, or a 1:1 ratio of two plasmids where stated) using lipofectamine 3000 as described by the manufacturer. Media was changed and Jurkat cells (1 × 106 cells/mL; 500 μL) were added in 10% FCS/RPMI at 16 h post-transfection. Positive control 25 ng/mL PMA/0.75 µg/mL ionomycin, or negative controls R10 alone. Cells were further incubated at 37 °C with 5% CO2 for 24 h before culture supernatant was removed for IL-2 analysis.

IL-2 ELISA

Capture antibody anti-human IL-2 (2 µg/mL; BD #555,051) in PBS was coated overnight at 4 °C. Wells were washed three times with 0.05% Tween20/PBS, prior to blocking with 1% BSA/PBS for ten minutes at room temperature and blocking solution flicked out. An IL-2 standard or cell supernatant was added to the wells and incubated overnight at 4 °C. Wells were washed as previously described and incubated with biotinylated anti-human IL-2 (1 µg/mL; BD #555,040) diluted in 1% BSA/PBS for one hour at 37 °C. After washing, wells were incubated with streptavidin horse radish peroxidase (1-in-5000 dilution; Roche #11,089,153,001) for one hour at 37 °C. Wells were washed and developed in 3,3′,5,5;-tetramethylbenzidine (Novex #00–2023), the reaction was then stopped by the addition of 2N H2SO4 and the plate read at 450 nm.

Results

A number of solid tumours express high TF levels [11, 13–16], we therefore aimed to test the utility of known anti-human TF monoclonal antibodies in the context of a CAR T cell or BiTE. To ensure the binding capacity of TF8-5G9 was not lost when the variable regions of this mAb were expressed as a scFvFc construct [32], we expressed the TF8-5G9 scFv and its antigen human TF as Fc fusion proteins (Fig. 1A). TF8-5G9 retained a high binding affinity (Kd = 0.37 nM) as determined by SPR (Fig. 1B).Fig. 1 TF8-5G9 anti-TF scFvFc binding affinity for human TF-Fc. Expi293F cells were transfected with pcDNA3.1(-) plasmids containing either TF8-5G9 scFvFc or human TF-Fc. Cell culture supernatant was harvested and Fc fusion protein purified via Protein A affinity chromatography column, followed by size exclusion chromatography. A TF8-5G9 anti-TF scFvFc and human TF-Fc (boiled and reduced; 1000, 500 and 100 ng) were run on an SDS-PAGE gel and Coomassie blue stained. Gel result representative of two independent Fc-fusion protein preparations. B Purified human TF-Fc antigen was immobilised by amine-coupling to CM5 Biacore sensor chips. A titration of purified TF8-5G9 scFvFc was allowed to bind for a contact time of 180 s at a flow rate of 30 µL/min, followed by a dissociation time of 600 s with a Biacore X100 SPR machine at pH 7.4. Titration curves in descending order: 18.75, 12.5, 9.375, 6.25 and 3.125 nM. SPR results representative of two repeats

We next constructed a second-generation CD3/CD28 CAR with c-Myc tag by utilising the TF8-5G9 scFv. This was cloned into a sleeping beauty transposon system with SfiI restriction sites [34], prior to its transfection into the Jurkat (Clone E6.1) cell line that is known to express high levels of IL-2 upon CD3/CD28 signalling. Successful transfection and expression were observed via the upregulation of the surrogate marker GFP, as well as the c-Myc tag within the CAR construct (Fig. 2A).Fig. 2 TF8-5G9 anti-TF CAR is specifically activated by human TF in vitro. A TF8-5G9 CAR-T or untransfected Jurkat cells were analysed for c-Myc and GFP expression by flow cytometry. IL-2 release from TF8-5G9 CAR-T or untransfected Jurkat was measured by ELISA following incubation for 24 h with B a titration of solid phase human TF, C negative controls nil antigen, murine TF or competitive inhibition with TF8-5G9 scFvFc, or D TF-expressing MDA-MB-231 cells, where stated positive controls PMA/ionomycin or 2.5 µg/mL solid phase human TF were included. Results representative of three independent repeats, B a single pilot experiment where points indicate mean ± SD of triplicate wells, and C and D bars indicate mean with SD error bars of three pooled independent experiments

The TF8-5G9 CAR showed a dose-dependent response upon exposure to HuTF with increasing levels of IL-2 detected (Fig. 2B). The TF8-5G9 CAR response could be neutralised by the inclusion of TF8-5G9 scFvFc emphasising the CAR’s specificity. Furthermore, no cross-species reactivity was noted in the presence of murine TF (Fig. 2C). Triple negative breast cancer cell line MDA-MB-231 has previously been shown to express TF [13], therefore we tested the CAR T cell capacity to recognise endogenous levels of TF. A clear response was observed with approximately 5 ng/mL IL-2 detected following incubation of TF8-5G9 CAR T cells with MDA-MB-231 (Fig. 2D).

In a similar manner to the TF8-5G9 CAR construct, we investigated the use of a second anti-human TF monoclonal antibody, hATR-5 [33]. hATR-5 scFv was found to have a high binding affinity (Kd = 0.46 nM) by SPR (Fig. 3A). The hATR-5 scFv when incorporated into a CAR construct was both surface expressed as shown by flow cytometric analysis of c-Myc expression, as well as functional, with a clear response against both solid-phase TF, as well as endogenously expressed TF on MDA-MB-231with IL-2 detected by ELISA (Fig. 3B and C).Fig. 3 hATR-5 anti-TF CAR targets TF-expressing tumour cell line in vitro. A Purified human TF-Fc antigen was immobilised by amine-coupling to CM5 Biacore sensor chips. A titration of purified hATR-5 scFvFc was allowed to bind for a contact time of 180 s at a flow rate of 30 µL/min, followed by a dissociation time of 600 s with a Biacore X100 SPR machine at pH 7.4. Titration curves in descending order: 18.75, 12.5, 9.375, 6.25 and 3.125 nM. SPR results representative of two repeats. B hATR CAR-T or untransfected Jurkat cells were analysed for c-Myc and RFP expression by flow cytometry. C IL-2 release from hATR-5 CAR-T or untransfected Jurkat was measured by ELISA following incubation for 24 h with TF-expressing MDA-MB-231 cells, 2.5 μg/mL solid phase human TF, cell only controls or positive control PMA/ionomycin. Results representative of two independent experiments. Bar indicates mean with SD error bars

To investigate the potential of utilising TF within a dual target system, we generated a BiTE that binds both human TF (TF8-5G9) and CD3 (OKT3) [35]. This BiTE was soluble and able to be purified from Expi293F secreting cells, however corresponding with previous studies a low yield indicated relatively low expression (data not shown). HEK293T cells were transiently transfected to express both the full-length TF antigen, as well as the anti-TF/CD3 BiTE. In the presence of Jurkat T cells, IL-2 was released indicating that the anti-TF/CD3 BiTE was functional (Fig. 4).Fig. 4 Anti-TF-anti-CD3 BiTE activates T cells in the presence of TF-expressing cells in vitro. A Expi293F cells were transfected with pSBbi-GP plasmid containing OKT3-TF85G9 BiTE. His-tagged protein was purified from cell culture supernatant via a Nickel-NTA column. OKT3-TF85G9 BiTE protein either not boiled/not reduced (nBnR) or boiled/reduced (BR) were run on an SDS-PAGE gel and Coomassie blue stained. Gel representative of at least two preparations. B HEK293T cells were transiently transfected or co-transfected with plasmids containing either human TF, anti-TF-anti-CD3 BiTE, or an empty vector as stated. At 16 h post-transfection, Jurkat T cells were added and further incubated for 24 h before IL-2 release was analysed by ELISA. Untransfected HEK293T with Jurkat cells or co-transfected TF/BiTE without Jurkat cells were used as additional negative controls, and PMA/ionomycin as a positive control. Bar indicates mean with SD error bars of three pooled independent experiments. One-way ANOVA with Bonferroni post-correction test performed: ns = not significant; * P < 0.05; **** P < 0.0001

Discussion

In this study, we developed CAR and BiTE from well-characterised monoclonal TF sequences, clones TF8-5G9 and hATR-5 [32, 33, 36]. For both antibodies, we demonstrated a preservation of TF binding affinity following conversion to scFv format (Kd 0.37 and 0.46 nM respectively; Fig. 1B and 2A). Previous reports of TF8-5G9 and hATR-5 Fab has shown high affinity binding (3.4 nM (Ki), and 0.85 nM) to the C-terminal side of the TF extracellular domain [33, 36]. This high affinity is largely contributed by the presence of 15 and 19 hydrogen bonds within the heavy and light chain CDRs of the TF8-5G9 and hATR-5 clones, respectively [33, 36].

While the development of a scFv into a CAR T cell can be a straightforward conversion, this is not always the case. scFv-derived CAR do not always show sufficient surface expression due to defective protein synthesis and/or inefficient transport to the cell surface. While, some scFv-derived CAR may show high surface expression but lack binding functionality due to the aggregation of CAR on the cell surface, or poor structural stability once cell surface-expressed [37]. In contrast, CDR-mediated CAR clustering has been shown to cause antigen-independent tonic signalling within CAR-T cells leading to T cell exhaustion [38]. We demonstrated the successful utility of anti-TF mAb constructs from the clones TF8-5G9 and hATR-5 for incorporation into a CAR format, as well as developing the first anti-TF BiTE bridging TF and CD3 on T cells (Figs. 2, 3 and 4).

The success of cancer immunotherapy is largely reliant on the TAA selected to target. Challenges arise when TAA are expressed elsewhere within the body. Both anti-TF CAR were surface expressed on human T cells and showed dose dependent cytokine release in response to solid-phase or cell-associated TF antigen. Similarly, the TF8-5G9 BiTE was expressed in a mammalian system and demonstrated the BiTE developed reacted specifically to TF. On-target off-tumour effects could be addressed by utilising conditional reactivity. This can be achieved by a variety of means including affinity detuning, mutation and masking to allow selective activation in the tumour environment. As part of our characterisation, we determined that both anti-TF scFvFc TF8-5G9 and hATR-5 have nanomolar binding affinities, as such there is greater flexibility to potentially reduce the binding affinity via rational or random mutagenesis to achieve micromolar binding affinities [39]. Where CAR still retain potent anti-tumour activity, while exhibiting superior safety profiles by sparing tissues with low antigen density, e.g. self-tissue as only high density antigen is able to trigger the CAR T cells [39–41].

The utilisation of dual recognition immunotherapies, e.g. BiTEs have the potential to not only improve the safety profile of TF-targeted cancer therapies by only activating T cells in the tumour vicinity. But have the added advantage of enhancing both CAR T cells, and/or endogenous TIL activation. Pre-clinical studies with BiTE AMG 596 targeting an anti-EGFRvIII tumour antigen and CD3 has shown promising results with prolonged survival of tumour bearing mice in vivo, thus demonstrating the clinical utility of BiTE technology [42]. Previous studies have shown promising results by the targeting of TF in a variety of approaches, including monoclonal antibody blockade, chimeric antigen receptor expressing cells, or modified anti-TF molecules. Tisotumab Vedotin, an anti-TF mAb (TF-011) drug conjugate has shown promising anti-tumour activity in clinical trials and is currently FDA-approved for recurrent and metastatic cervical cancer [43, 44]. Zhu et al. utilised TF-011 in an alternative context with the construction of a T cell engaging bispecific antibody (TCB) which utilised TF-011 light chains linked by their C-termini to anti-CD3 (OKT3) scFv [45]. They showed significant anti-tumour activity both in vitro and in vivo with the anti-TF/CD3 TCB. Alternatively, while traditional CAR utilise an immunoglobulin-derived scFv fragment, a promising non-traditional 3rd generation anti-TF CAR T cell was created utilising the Factor VII light chain rather than a scFv [46].

Doxorubicin-encapsulated liposomes were effectively targeted to both TF-expressing tumour cells via the use of anti-TF Fab fragments PEG-conjugated to liposomes. Tumour-bearing mice showed both reduced tumour growth and increased survival when treated with these liposomes. Moreover, the importance of targeting both the tumour directly, in addition to surrounding TF-rich stromal cells within the tumour microenvironment was shown via the use of liposomes conjugated to both anti-human and anti-murine TF antibodies, where pancreatic tumour cells (BxPC3) of human origin were xenografted into mice, while the stromal cells of the tumour microenvironment were of murine origin [47]. Overall, a diverse range of immunotherapies utilising anti-TF mAb to target tumours are currently being researched and show promise, thus the addition of new sequences to the library of successfully expressed and functional anti-TF scFv will further aid research.

A limitation of this study is that the CAR was only tested in vitro. Future work will be required to determine if anti-TF CAR and BiTE will be effective against solid tumours in a preclinical model. Because the TF8-5G9 anti-TF CAR showed no reaction to murine TF, this would allow in vivo mouse experiments to performed without concern of any on-target off-tumour effects of using this particular scFv clone. However, to fully determine safety of such a construct, backcrossing of the huTF allele from existing lines into NSG mice would be required for adoptive transfer of human CAR T cells and testing of human tumour cell lines [48].

This work provides a template for the future development of anti-TF agents to target solid tumours. A primary requirement for TF-targeting strategies will be enforcing conditional activity of such agents specifically at the tumour site. Therefore, the CAR and BiTE formats developed here are a first step towards incorporation into a conditional or inducible activation logic.

Supplementary Information

Below is the link to the electronic supplementary material.Supplementary file1 (DOCX 19 kb)

Author contributions

SCS and AM wrote the manuscript; SCS performed experiments represented in Fig. 1; SCS performed the experiments represented in Fig. 2; SCS, JH and GT performed the experiments in Fig. 3; SCS and PS performed the experiments represented in Fig. 4.

Funding

Open Access funding enabled and organized by CAUL and its Member Institutions.

Data availability

No datasets were generated or analysed during the current study.

Declarations

Conflict of interest

The authors declare no conflict of interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. White LG Goy HE Rose AJ McLellan AD Controlling cell trafficking: addressing failures in CAR T and NK cell therapy of solid tumours Cancers 2022 14 978 10.3390/cancers14040978 35205725
White LG, Goy HE, Rose AJ, McLellan AD (2022) Controlling cell trafficking: addressing failures in CAR T and NK cell therapy of solid tumours. Cancers 14:978. 10.3390/cancers1404097835205725 10.3390/cancers14040978
2. Flugel CL Majzner RG Krenciute G Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours Nat Rev Clin Oncol 2023 20 49 62 10.1038/s41571-022-00704-3 36418477
Flugel CL, Majzner RG, Krenciute G et al (2023) Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol 20:49–62. 10.1038/s41571-022-00704-336418477 10.1038/s41571-022-00704-3
3. Bailey SR Berger TR Graham C Four challenges to CAR T cells breaking the glass ceiling Eur J Immunol 2023 53 1 8 10.1002/eji.202250039
Bailey SR, Berger TR, Graham C et al (2023) Four challenges to CAR T cells breaking the glass ceiling. Eur J Immunol 53:1–8. 10.1002/eji.20225003910.1002/eji.202250039
4. Morgan RA Yang JC Kitano M Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 Mol Ther 2010 18 843 851 10.1038/mt.2010.24 20179677
Morgan RA, Yang JC, Kitano M et al (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18:843–851. 10.1038/mt.2010.2420179677 10.1038/mt.2010.24
5. Li J Li W Huang K Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward J Hematol Oncol 2018 11 22 10.1186/s13045-018-0568-6 29433552
Li J, Li W, Huang K et al (2018) Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward. J Hematol Oncol 11:22. 10.1186/s13045-018-0568-629433552 10.1186/s13045-018-0568-6
6. Labanieh L Mackall CL CAR immune cells: design principles, resistance and the next generation Nature 2023 614 635 648 10.1038/s41586-023-05707-3 36813894
Labanieh L, Mackall CL (2023) CAR immune cells: design principles, resistance and the next generation. Nature 614:635–648. 10.1038/s41586-023-05707-336813894 10.1038/s41586-023-05707-3
7. Thirumalaisamy R Vasuki S Sindhu SM FDA-approved chimeric antigen receptor (CAR)-T cell therapy for different cancers-a recent perspective Mol Biotechnol 2024 10.1007/s12033-024-01090-0 38459361
Thirumalaisamy R, Vasuki S, Sindhu SM et al (2024) FDA-approved chimeric antigen receptor (CAR)-T cell therapy for different cancers-a recent perspective. Mol Biotechnol. 10.1007/s12033-024-01090-038459361 10.1007/s12033-024-01090-0
8. Haynes NM Trapani JA Teng MWL Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors Blood 2002 100 3155 3163 10.1182/blood-2002-04-1041 12384413
Haynes NM, Trapani JA, Teng MWL et al (2002) Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 100:3155–3163. 10.1182/blood-2002-04-104112384413 10.1182/blood-2002-04-1041
9. Pulè MA Straathof KC Dotti G A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells Mol Ther 2005 12 933 941 10.1016/j.ymthe.2005.04.016 15979412
Pulè MA, Straathof KC, Dotti G et al (2005) A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 12:933–941. 10.1016/j.ymthe.2005.04.01615979412 10.1016/j.ymthe.2005.04.016
10. Arvedson T Bailis JM Britten CD Targeting solid tumors with bispecific T cell engager immune therapy Annu Rev Cancer Biol 2022 6 17 34 10.1146/annurev-cancerbio-070620-104325
Arvedson T, Bailis JM, Britten CD et al (2022) Targeting solid tumors with bispecific T cell engager immune therapy. Annu Rev Cancer Biol 6:17–34. 10.1146/annurev-cancerbio-070620-10432510.1146/annurev-cancerbio-070620-104325
11. Mueller BM Reisfeld RA Edgington TS Ruf W Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis Proc Natl Acad Sci U S A 1992 89 11832 11836 10.1073/pnas.89.24.11832 1465406
Mueller BM, Reisfeld RA, Edgington TS, Ruf W (1992) Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci U S A 89:11832–118361465406 10.1073/pnas.89.24.11832
12. Breij ECW De Goeij BECG Verploegen S An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors Cancer Res 2014 74 1214 1226 10.1158/0008-5472.CAN-13-2440 24371232
Breij ECW, De Goeij BECG, Verploegen S et al (2014) An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. Cancer Res 74:1214–1226. 10.1158/0008-5472.CAN-13-244024371232 10.1158/0008-5472.CAN-13-2440
13. Zhang X Li Q Zhao H Pathological expression of tissue factor confers promising antitumor response to a novel therapeutic antibody SC1 in triple negative breast cancer and pancreatic adenocarcinoma Oncotarget 2017 8 59086 59102 10.18632/oncotarget.19175 28938620
Zhang X, Li Q, Zhao H et al (2017) Pathological expression of tissue factor confers promising antitumor response to a novel therapeutic antibody SC1 in triple negative breast cancer and pancreatic adenocarcinoma. Oncotarget 8:59086–59102. 10.18632/oncotarget.1917528938620 10.18632/oncotarget.19175
14. Rydén L Grabau D Schaffner F Evidence for tissue factor phosphorylation and its correlation with protease-activated receptor expression and the prognosis of primary breast cancer Int J Cancer 2010 126 2330 2340 10.1002/ijc.24921 19795460
Rydén L, Grabau D, Schaffner F et al (2010) Evidence for tissue factor phosphorylation and its correlation with protease-activated receptor expression and the prognosis of primary breast cancer. Int J Cancer 126:2330–2340. 10.1002/ijc.2492119795460 10.1002/ijc.24921
15. Hjortoe GM Petersen LC Albrektsen T Tissue factor-factor VIIa – specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration Blood 2004 103 3029 3038 10.1182/blood-2003-10-3417.Supported 15070680
Hjortoe GM, Petersen LC, Albrektsen T et al (2004) Tissue factor-factor VIIa – specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood 103:3029–3038. 10.1182/blood-2003-10-3417.Supported15070680 10.1182/blood-2003-10-3417.Supported
16. Khorana AA Ahrendt SA Ryan CK Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer Clin Cancer Res 2007 13 2870 2875 10.1158/1078-0432.CCR-06-2351 17504985
Khorana AA, Ahrendt SA, Ryan CK et al (2007) Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 13:2870–2875. 10.1158/1078-0432.CCR-06-235117504985 10.1158/1078-0432.CCR-06-2351
17. Hu Z Shen R Campbel A Targeting tissue factor for immunotherapy of triple-negative breast cancer using a second-generation ICON Cancer Immunol Res 2018 6 671 684 10.1158/2326-6066.CIR-17-0343 29622581
Hu Z, Shen R, Campbel A et al (2018) Targeting tissue factor for immunotherapy of triple-negative breast cancer using a second-generation ICON. Cancer Immunol Res 6:671–684. 10.1158/2326-6066.CIR-17-034329622581 10.1158/2326-6066.CIR-17-0343
18. Cesarman-Maus G Braggio E Lome-Maldonado C Absence of tissue factor is characteristic of lymphoid malignancies of both T- and B-cell origin Thromb Res 2014 133 606 609 10.1016/j.thromres.2014.01.020 24491425
Cesarman-Maus G, Braggio E, Lome-Maldonado C et al (2014) Absence of tissue factor is characteristic of lymphoid malignancies of both T- and B-cell origin. Thromb Res 133:606–609. 10.1016/j.thromres.2014.01.02024491425 10.1016/j.thromres.2014.01.020
19. Van Den Berg YW Osanto S Reitsma PH Versteeg HH The relationship between tissue factor and cancer progression: insights from bench and bedside Blood 2012 119 924 932 10.1182/blood-2011-06-317685 22065595
Van Den Berg YW, Osanto S, Reitsma PH, Versteeg HH (2012) The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood 119:924–932. 10.1182/blood-2011-06-31768522065595 10.1182/blood-2011-06-317685
20. Mueller BM Ruf W Requirement for binding of catalitically active factor VIIa in tissue factor dependent metastasis J Clin Invest 1998 101 1372 1378 10.1172/JCI930 9525979
Mueller BM, Ruf W (1998) Requirement for binding of catalitically active factor VIIa in tissue factor dependent metastasis. J Clin Invest 101:1372–13789525979 10.1172/JCI930
21. Gil-Bernabé AM Ferjancic S Tlalka M Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice Blood 2012 119 3164 3175 10.1182/blood-2011-08-376426 22327225
Gil-Bernabé AM, Ferjancic S, Tlalka M et al (2012) Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice. Blood 119:3164–3175. 10.1182/blood-2011-08-37642622327225 10.1182/blood-2011-08-376426
22. Magnus N Garnier D Meehan B Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations Proc Natl Acad Sci U S A 2014 111 3544 3549 10.1073/pnas.1314118111 24520174
Magnus N, Garnier D, Meehan B et al (2014) Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations. Proc Natl Acad Sci U S A 111:3544–3549. 10.1073/pnas.131411811124520174 10.1073/pnas.1314118111
23. Van Den Berg YW Van Den Hengel LG Myers HR Alternatively spliced tissue factor induces angiogenesis through integrin ligation Proc Natl Acad Sci U S A 2009 106 19497 19502 10.1073/pnas.0905325106 19875693
Van Den Berg YW, Van Den Hengel LG, Myers HR et al (2009) Alternatively spliced tissue factor induces angiogenesis through integrin ligation. Proc Natl Acad Sci U S A 106:19497–19502. 10.1073/pnas.090532510619875693 10.1073/pnas.0905325106
24. Hobbs JE Zakarija A Cundiff DL Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model Thromb Res 2007 120 13 21 10.1016/S0049-3848(07)70126-3
Hobbs JE, Zakarija A, Cundiff DL et al (2007) Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model. Thromb Res 120:13–21. 10.1016/S0049-3848(07)70126-310.1016/S0049-3848(07)70126-3
25. Bromberg ME Konigsberg WH Madison JF Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation PNAS 1995 92 8205 8209 10.1073/pnas.92.18.8205 7667269
Bromberg ME, Konigsberg WH, Madison JF et al (1995) Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. PNAS 92:8205–8209. 10.1073/pnas.92.18.82057667269 10.1073/pnas.92.18.8205
26. Muhsin-Sharafaldine MR Kennedy BR Saunderson SC Mechanistic insight into the procoagulant activity of tumor-derived apoptotic vesicles Biochim Biophys Acta Gen Subj 2017 1861 286 295 10.1016/j.bbagen.2016.11.020 27864149
Muhsin-Sharafaldine MR, Kennedy BR, Saunderson SC et al (2017) Mechanistic insight into the procoagulant activity of tumor-derived apoptotic vesicles. Biochim Biophys Acta Gen Subj 1861:286–295. 10.1016/j.bbagen.2016.11.02027864149 10.1016/j.bbagen.2016.11.020
27 Muhsin-Sharafaldine M-R Saunderson SC Dunn AC Procoagulant and immunogenic properties of melanoma exosomes, microvesicles and apoptotic vesicles Oncotarget 2016 7 56279 56294 10.18632/oncotarget.10783 27462921
Muhsin-Sharafaldine M-R, Saunderson SC, Dunn AC et al (2016) Procoagulant and immunogenic properties of melanoma exosomes, microvesicles and apoptotic vesicles. Oncotarget 7:56279–56294. 10.18632/oncotarget.1078327462921 10.18632/oncotarget.10783
28. Mackman N Tilley RE Key NS Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis Arterioscler Thromb Vasc Biol 2007 27 1687 1693 10.1161/ATVBAHA.107.141911 17556654
Mackman N, Tilley RE, Key NS (2007) Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol 27:1687–1693. 10.1161/ATVBAHA.107.14191117556654 10.1161/ATVBAHA.107.141911
29. Grover SP Mackman N Tissue factor: an essential mediator of hemostasis and trigger of thrombosis Arterioscler Thromb Vasc Biol 2018 38 709 725 10.1161/ATVBAHA.117.309846 29437578
Grover SP, Mackman N (2018) Tissue factor: an essential mediator of hemostasis and trigger of thrombosis. Arterioscler Thromb Vasc Biol 38:709–725. 10.1161/ATVBAHA.117.30984629437578 10.1161/ATVBAHA.117.309846
30. Drake TA Morrissey JH Edgington TS Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis Am J Pathol 1989 134 1087 1097 2719077
Drake TA, Morrissey JH, Edgington TS (1989) Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 134:1087–10972719077
31. Morrissey JH Revak D Tejada P Resolution of monomeric and heterodimeric forms of tissue factor, the high-affinity cellular receptor for factor VII Thromb Res 1988 50 481 493 10.1016/0049-3848(88)90197-1 3413716
Morrissey JH, Revak D, Tejada P et al (1988) Resolution of monomeric and heterodimeric forms of tissue factor, the high-affinity cellular receptor for factor VII. Thromb Res 50:481–493. 10.1016/0049-3848(88)90197-13413716 10.1016/0049-3848(88)90197-1
32. Ruf W Stura EA LaPolla RJ Purification, sequence and crystallization of an anti-tissue factor Fab and its use for the crystallization of tissue factor J Cryst Growth 1992 122 253 264 10.1016/0022-0248(92)90254-G
Ruf W, Stura EA, LaPolla RJ et al (1992) Purification, sequence and crystallization of an anti-tissue factor Fab and its use for the crystallization of tissue factor. J Cryst Growth 122:253–264. 10.1016/0022-0248(92)90254-G10.1016/0022-0248(92)90254-G
33. Ohto U Mizutani R Nakamura M Crystal structure of a humanized Fab fragment of anti-tissue-factor antibody in complex with tissue factor J Synchrotron Radiat 2004 11 105 108 10.1107/s0909049503023513 14646147
Ohto U, Mizutani R, Nakamura M et al (2004) Crystal structure of a humanized Fab fragment of anti-tissue-factor antibody in complex with tissue factor. J Synchrotron Radiat 11:105–108. 10.1107/s090904950302351314646147 10.1107/s0909049503023513
34. Kowarz E Löscher D Marschalek R Optimized sleeping beauty transposons rapidly generate stable transgenic cell lines Biotechnol J 2015 10 647 653 10.1002/biot.201400821 25650551
Kowarz E, Löscher D, Marschalek R (2015) Optimized sleeping beauty transposons rapidly generate stable transgenic cell lines. Biotechnol J 10:647–653. 10.1002/biot.20140082125650551 10.1002/biot.201400821
35. Singh A Dees S Grewal IS Overcoming the challenges associated with CD3+ T-cell redirection in cancer Br J Cancer 2021 124 1037 1048 10.1038/s41416-020-01225-5 33469153
Singh A, Dees S, Grewal IS (2021) Overcoming the challenges associated with CD3+ T-cell redirection in cancer. Br J Cancer 124:1037–1048. 10.1038/s41416-020-01225-533469153 10.1038/s41416-020-01225-5
36. Huang MD Syed R Stura EA The mechanism of an inhibitory antibody on TF-initiated blood coagulation revealed by the crystal structures of human tissue factor, Fab5G9 and TF center dot 5G9 complex J Mol Biol 1998 275 873 894 10.1006/jmbi.1997.1512 9480775
Huang MD, Syed R, Stura EA et al (1998) The mechanism of an inhibitory antibody on TF-initiated blood coagulation revealed by the crystal structures of human tissue factor, Fab5G9 and TF center dot 5G9 complex. J Mol Biol 275:873–8949480775 10.1006/jmbi.1997.1512
37. Fujiwara K Masutani M Tachibana M Okada N Impact of scFv structure in chimeric antigen receptor on receptor expression efficiency and antigen recognition properties Biochem Biophys Res Commun 2020 527 350 357 10.1016/j.bbrc.2020.03.071 32216966
Fujiwara K, Masutani M, Tachibana M, Okada N (2020) Impact of scFv structure in chimeric antigen receptor on receptor expression efficiency and antigen recognition properties. Biochem Biophys Res Commun 527:350–357. 10.1016/j.bbrc.2020.03.07132216966 10.1016/j.bbrc.2020.03.071
38. Sarén T Saronio G Marti Torrell P Complementarity-determining region clustering may cause CAR-T cell dysfunction Nat Commun 2023 14 1 11 10.1038/s41467-023-40303-z 36596776
Sarén T, Saronio G, Marti Torrell P et al (2023) Complementarity-determining region clustering may cause CAR-T cell dysfunction. Nat Commun 14:1–11. 10.1038/s41467-023-40303-z36596776 10.1038/s41467-023-40303-z
39. Park S Shevlin E Vedvyas Y Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity Sci Rep 2017 7 1 15 10.1038/s41598-017-14749-3 28127051
Park S, Shevlin E, Vedvyas Y et al (2017) Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity. Sci Rep 7:1–15. 10.1038/s41598-017-14749-328127051 10.1038/s41598-017-14749-3
40. Liu X Jiang S Fang C Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice Cancer Res 2015 75 3596 3607 10.1158/0008-5472.CAN-15-0159 26330166
Liu X, Jiang S, Fang C et al (2015) Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice. Cancer Res 75:3596–3607. 10.1158/0008-5472.CAN-15-015926330166 10.1158/0008-5472.CAN-15-0159
41. Zuckier LS Berkowitz EZ Sattenberg RJ Influence of affinity and antigen density on antibody localization in a modifiable tumor targeting model Cancer Res 2000 60 7008 7013 11156404
Zuckier LS, Berkowitz EZ, Sattenberg RJ et al (2000) Influence of affinity and antigen density on antibody localization in a modifiable tumor targeting model. Cancer Res 60:7008–701311156404
42. Sternjak A Lee F Thomas O Preclinical assessment of AMG 596, a bispecific T-cell engager (BiTE) immunotherapy targeting the tumor-specific antigen EGFRvIII Mol Cancer Ther 2021 20 925 933 10.1158/1535-7163.MCT-20-0508 33632870
Sternjak A, Lee F, Thomas O et al (2021) Preclinical assessment of AMG 596, a bispecific T-cell engager (BiTE) immunotherapy targeting the tumor-specific antigen EGFRvIII. Mol Cancer Ther 20:925–933. 10.1158/1535-7163.MCT-20-050833632870 10.1158/1535-7163.MCT-20-0508
43. Markham A Tisotumab vedotin: first approval Drugs 2021 81 2141 2147 10.1007/s40265-021-01633-8 34748188
Markham A (2021) Tisotumab vedotin: first approval. Drugs 81:2141–2147. 10.1007/s40265-021-01633-834748188 10.1007/s40265-021-01633-8
44. Coleman RL Lorusso D Gennigens C Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study Lancet Oncol 2021 22 609 619 10.1016/S1470-2045(21)00056-5 33845034
Coleman RL, Lorusso D, Gennigens C et al (2021) Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 22:609–619. 10.1016/S1470-2045(21)00056-533845034 10.1016/S1470-2045(21)00056-5
45. Pan Z Chen J Xiao X Characterization of a novel bispecific antibody targeting tissue factor-positive tumors with T cell engagement Acta Pharm Sin B 2022 12 1928 1942 10.1016/j.apsb.2021.10.028 35847491
Pan Z, Chen J, Xiao X et al (2022) Characterization of a novel bispecific antibody targeting tissue factor-positive tumors with T cell engagement. Acta Pharm Sin B 12:1928–1942. 10.1016/j.apsb.2021.10.02835847491 10.1016/j.apsb.2021.10.028
46. Zhang Q Wang H Li H Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice Oncotarget 2016 8 9488 9499 10.18632/oncotarget.14367
Zhang Q, Wang H, Li H et al (2016) Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice. Oncotarget 8:9488–9499. 10.18632/oncotarget.1436710.18632/oncotarget.14367
47. Shimizu K Takeuchi Y Otsuka K Development of tissue factor-targeted liposomes for effective drug delivery to stroma-rich tumors J Control Release 2020 323 519 529 10.1016/j.jconrel.2020.04.043 32360306
Shimizu K, Takeuchi Y, Otsuka K et al (2020) Development of tissue factor-targeted liposomes for effective drug delivery to stroma-rich tumors. J Control Release 323:519–529. 10.1016/j.jconrel.2020.04.04332360306 10.1016/j.jconrel.2020.04.043
48. Parry GCN Erlich JH Carmeliet P Low levels of tissue factor are compatible with development and hemostasis in mice J Clin Invest 1998 101 560 569 10.1172/JCI814 9449688
Parry GCN, Erlich JH, Carmeliet P et al (1998) Low levels of tissue factor are compatible with development and hemostasis in mice. J Clin Invest 101:560–569. 10.1172/JCI8149449688 10.1172/JCI814
